CervoMed is a Boston biotechnology company developing neflamapimod, an oral drug candidate for age-related brain disorders. CRVO reports earnings on Thu, Nov 12, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 10 | Canaccord Genuity | Maintained | Buy | |
| Jul 9 | HC Wainwright & Co. | Reiterated | Buy |
Whale Options Flow
90DNo whale options trades in CRVO in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CRVO is in one of them and how their past CRVO trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CRVO in an article yet. Here's the latest on the wider market.
About CervoMed
CervoMed is a biotechnology company based in Boston, Massachusetts, that is developing treatments for brain disorders linked to aging. Its lead candidate, neflamapimod, is an oral drug designed to reduce brain inflammation and address problems with communication between nerve cells. The drug is in clinical trials for dementia with Lewy bodies and is also being studied for other neurological conditions, including ALS. The company does not yet have an approved product, and its intended users are patients with these conditions.
- Headquarters
- Boston, MA